Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 system; integrated fluidic circuits (IFCs) consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. The company also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules. It serves academic institutions; clinical research laboratories; biopharmaceutical, biotechnology, and agricultural biotechnology companies; and contract research organizations. Fluidigm Corporation distributes its systems through direct sales force and support organizations located in North America, Europe, and the Asia-Pacific, and through distributors or sales agents in various European, Latin American, Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
http://www.priceseries.com/trade/FLDM-Fluidigm-Corporation-stock-gains-45-percent-a-Trade-Record-by-priceSeries-2019020820190326.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments